Clinical trial NCT04836013: Combined Lactobacilli (Reuteri LMG P-27481 and GG ATCC 53103) to Prevent Antibiotic Associated Symptoms in Children
Official title: Multicenter Randomized Trial of a Combined Probiotic (Lactobacillus Reuteri LMG P-27481 and Lactobacillus Rhamnosus GG (ATCC 53103) for the Prevention of Antibiotic-Associated Diarrhea and Gastrointestinal Symptoms in Children
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Diarrhea Caused by Drug
Abdominal Pain
Keywords: antibiotics
diarrhea
probiotics
Lactobacillus
children
abdominal pain
Lead sponsor: Università degli Studi dell'Insubria
Sponsor class: OTHER
First posted: 2021-04-08
Enrollment: 216
Sex: ALL
Minimum age (years): 12
Maximum age (years): 12
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Double blind placebo controlled prospective trial
Primary purpose: PREVENTION

Brief summary: This is a prospective multicenter pediatric double-blind, randomized placebo-controlled, parallel group clinical trial intended to evaluate the efficacy, safety and tolerability of a combined probiotic (LGG and L. reuteri LMG P-27481) in the prevention of antibiotic associated diarrhea and gastrointestinal symptoms in hospitalised children treated with antibiotics for proven or suspected bacterial infection.

Detailed description: Eligible children will be randomly assigned to receive the combined probiotic study product (Noos, Roma, Italia)(BCCMTM Bacterial Collection of Ghent, Belgium, Italian Patent: 102016000011071, International Patent Request : PCT/IB 2017/053856), or placebo as additional treatment to the antibiotic therapy. Kind, dose and duration of antibiotic treatment will be decided by the local clinicians according to good medical practice and current recommendations. The first dose of probiotic will be started the same day of starting the antibiotic treatment, immediately after enrollment. Then, each oral stick will be administered orally once daily, in the morning, before breakfast, during the antibiotic treatment and prolonged for 30 days since starting.

Study product The combined probiotic is made by Lactobacillus reuteri LMG P-27481 and Lactobacillus rhamnosus GG (ATCC 53103), sucralose and isomalt as an oral stick formulation of 1.6 g with a concentration of probiotic of 2x1010 colony forming unit (CFU) per stick, launched in the Italian market with the name of Reuterin®GG (Noos, Roma, Italia).

The probiotic and placebo will be prepared centrally by the probiotic producer as identically appearing oral stick. The placebo will contain only sucralose and isomalt, 1.6 g per stick.

Randomization The allocation sequences and randomization lists has been generated by a online computer system. The probiotic -placebo allocation ratio will be of 1:1. To ensure allocation concealment, an independent subject prepared the randomization schedule and sealed envelopes to be sent to the participant centers. Each investigator will control the packaging and labels of trial treatments sent by the producer with a numerical code with no possible identification of the probiotic product compared to the placebo. The allocation will be consecutively assigned for all enrolled subjects. All investigators, participants, and statisticians will be blinded to the assigned treatment throughout the study and during the data analysis. After completing the analysis of the data or in case of sever adverse event the randomization code will be broken and information about the content of the product (probiotic or placebo) will be revealed by the producer, upon the investigator's request.

Monitoring and collection of data At enrollment a standardized form will record age, gender, anthropometric parameters, vital signs, refilling time, site of infection, laboratory tests, kind, dose and route of administration of antibiotic, diet, previous AAD or other gastrointestinal symptoms, comorbidity and associated treatment. Vesikary scale, anthropometric measures, vital signs, refilling time will be also recorded in each patient at enrollment and in case of occurrence of diarrhea. Bristol stool chart will be used to grade the consistency of stools.

Parents or care givers of each children will be instructed to fill in a diary to record the duration of antibiotic treatment and/or other treatment, the intake of the study product, the frequency of daily bowel movements, the consistency of stools (according to the Bristol stool scale), the frequency and intensity (according to a VAS scale, from 0 to 10) of abdominal pain, the presence and duration of fever, vomiting or any other symptoms they considered important, diet changes and general well being (according to a numerical 1-10 scale). The diary will be completed daily for the duration of the probiotic treatment and then weekly till the end of the study. After discharge from the hospital the absence from day care or school, the need of new antibiotic treatment or re-hospitalization will be also noted. In case of diarrhea, fever or other severe symptoms after hospital discharge parents will be instructed to contact the local pediatrician and investigator for clinical evaluation and stool analysis. A clinical visit will be scheduled in all recruited patients after 1, 3 and 6 months from enrollment.

Re-hospitalization will be required in case of severe infection, severe dehydration or whenever considered necessary by clinicians.

Scheduled investigations In all cases presenting diarrhea at least three stool samples will be collected and stool tests will be performed to detect viral, bacterial or C. difficile pathogens. Blood and urine test or radiologial investigations will be decided by the local clinician based on patient's clinical presentation and according to guidelines and good clinical practice.

One additional sample of stools will be collected, whenever possible, in each patient at enrollment, at 1, 3 and 6 months to evaluate fecal calprotectin to indirectly assess intestinal inflammation. In a subgroup of patients (the first 30 recruited in each arms) two other stool samples and a urine sample will be collected and stocked in freezer (-20° C) at the same study point for possible future additional explorative analysis of fecal inflammatory markers (lactoferrine, IgA, IL10 and TNF-α) and metabolomic profile (urine metabolites).

The probiotic producer (Noos S.r.L, Roma, Italia) will gift the probiotic product and placebo for the duration of the study for all children enrolled but has and will have no role in the design and conduct of the study; collection, management, analysis, or interpretation of the data; preparation, review, or approval of the manuscript; or the decision to submit the manuscript for publication. The data of the enrolled subjects will be managed, stored and property of the clinical investigators of the participant centers and of the coordinator center and will be analysed and published anonymously and as aggregate, in the respect of the current legislation on privacy.

Eligibility criteria: Inclusion Criteria (all of the following):

* Children aged 12 months to 12 years
* Proven or suspected bacterial infection
* Inpatient children needed antibiotic treatment
* Oral or intravenous or intramuscular antibiotic administration with at least 2 days of duration
* Parental informed consent to the participation to the study

Exclusion Criteria:

* Age below 12 months or above 12 years
* Infections with no or only one day of antibiotic treatment
* Sepsis or severe generalized infection
* Pancreatitis
* Known immunodeficiency or chronic gastrointestinal diseases or heart disease
* Oncologic patients
* Severe neurological impairment or lack of verbal expression
* Enteral or parenteral nutrition
* Gastrointestinal malformations or abdominal surgical interventions
* Central line catheter
* Acute or chronic diarrhea when starting antibiotics
* Current or recent (in the last four weeks) use of any probiotic product
* Antibiotic treatment started earlier than 24 hours before enrollment
* Absence of parental consent

Primary outcomes:
measure: Incidence of antibiotic-associated diarrhea, defined as episodes of otherwise unexplained diarrhea (≥3 loose or liquid stools per day with negative viral and bacterial stool tests), recorded by instructed parents in a structured daily diary.
timeFrame: From the second day after starting antibiotic treatment to 2 weeks after stopping antibiotics
Secondary outcomes:
measure: Number of children with episodes of infective diarrhea; dehydration (by Vesikary scale), fever, abdominal pain, vomiting and constipation (by Bristol stool chart); general well being (by 1-10 scale) as assessed by patient's record form.
timeFrame: 6 months from enrolling
Other outcomes:
measure: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
timeFrame: From enrolling to all the period of intervention (1 month)
measure: Number of participants with abnormal fecal inflammatory markers (calprotectin, lactoferrine, IgA, IL10 and TNF-α) and urine metabolomic profile
timeFrame: The additional stool and urine sample will be collected at recruitment, after 1 month and after 6 months from enrollment.
Locations:
city: Varese
country: Italy
facility: Silvia Salvatore
Study officials:
References: